# Anocca

Source: https://onco.cc/companies/anocca/  
OnCo record `anocca` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Anocca is a Swedish cell-therapy company building T-cell receptor therapies (TCR-T) that recognise targets from inside cancer cells, with a lab platform that replicates T-cell biology and software to pick the targets.

## Summary

Anocca, based in Södertälje south of Stockholm, describes itself as creating a pipeline of precision T-cell immunotherapies by combining a novel approach to T-cell biology, biotechnologies that replicate T-cell biology in the lab and integrated software for target discovery. Its focus is TCR-T therapy, in which the T cells of a patient are given a receptor that recognises a peptide from inside the cancer cell presented on HLA, reaching targets that antibodies and CAR-T cells cannot. The first clinical programme, a TCR-T directed at mutant KRAS, entered a first-in-human trial in 2024. The website does not state funding, listing or partners.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Anocca AB
- Tags: ctgov-sponsor; owner-request; tcr-t
- HQ: Södertälje, Sweden
- Type: cell-therapy
- Website: https://anocca.com

## Sources

- Official website: https://anocca.com

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- targets: [KRAS](https://onco.cc/targets/kras/)

---
JSON: https://onco.cc/api/v1/entities/anocca.json